In this article, we will look at the 10 Fastest Growing NYSE Stocks to Buy.
Fast-growing stocks continue to attract investor attention as earnings momentum remains a key driver of equity market performance. In its 2026 Economic and Market Outlook, Vanguard highlights the continued strength of technology-driven growth trends, noting that “U.S. technology stocks could well maintain their momentum given the rate of investment and anticipated earnings growth.” At the same time, the firm cautions that “risks are growing amid this exuberance,” underscoring that investors should remain selective.
Vanguard’s outlook suggests that while enthusiasm surrounding high-growth companies remains strong, the key differentiator will be the ability to sustain revenue expansion supported by structural trends. Technologies such as artificial intelligence, cloud computing, and advanced digital infrastructure continue to attract significant capital investment, helping fuel earnings growth among companies positioned at the center of these ecosystems.
Other asset managers share a similarly constructive perspective on growth-driven opportunities. In its 2026 Year-Ahead Investment Outlook, J.P. Morgan Asset Management notes that “profit growth has been impressive, tracking for four consecutive quarters of double-digit earnings growth.” The firm also emphasizes that “within stocks, we continue to see the biggest opportunities in structural rather than cyclical stories,” highlighting a preference for companies benefiting from long-term secular drivers rather than short-term macro cycles.
Taken together, these perspectives indicate that companies delivering sustained revenue expansion and benefiting from powerful structural trends remain well-positioned in the current environment. With this in mind, we’ll look at the 10 Fastest Growing NYSE Stocks to Buy.
Our Methodology
We used the Finviz screener to identify NYSE stocks that have achieved more than 50% sales growth over the past year and more than 50% growth over the past three years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. Brookfield Asset Management Ltd. (NYSE:BAM)
On February 17, 2026, Morgan Stanley raised its price target on Brookfield Asset Management to $63 from $62 and maintained an Equal Weight rating, updating its model following the Q4 report.
Earlier in February, Brookfield Asset Management reported Q4 EPS of 47c, compared to the 44c consensus estimate. Fee-bearing capital grew to $603B, up 12% year over year, driven by record quarterly fundraising of $35B and $112B in the last year. CEO Connor Teskey said, “2025 was another record year for our business,” citing results “across each of fundraising, deployment, and monetizations.” He added that fee-bearing capital grew “to over $600B,” with “22% year-over-year growth in fee-related earnings” and “14% growth in distributable earnings.” Teskey said the company will have “key flagship strategies in the market” and a “growing suite of complementary offerings,” which supports the decision “to increase our dividend by 15%.”
The board declared a quarterly dividend of 50.25c per share, representing a 15% increase, payable on March 31 to shareholders of record as of the close of business on February 27.
Brookfield Asset Management Ltd. (NYSE:BAM) is a private equity firm specializing in acquisitions and growth capital investments, typically investing in renewable power and transition, and infrastructure sectors.
9. Hims & Hers Health, Inc. (NYSE:HIMS)
On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 and kept an Overweight rating on the shares. That same day, TD Cowen analyst Jonna Kim lowered the firm’s price target to $17 from $20 and maintained a Hold rating, citing near-term pressure until there is more clarity on regulatory implications around compounded injectable GLP-1s and improvement in the underlying core business momentum.
Morgan Stanley analyst Craig Hettenbach also reduced the firm’s price target to $21 from $40 and kept an Equal Weight rating. The analyst said 2026 revenue guidance “surprisingly” came in about 2% ahead of the Street view, but EBITDA guidance was about 8% below consensus, confirming concerns about increased investment.
On February 23, 2026, Hims & Hers Health reported Q4 EPS of 8c, compared to the 19c consensus estimate. Q4 revenue was $617.82M, versus consensus of $617.25M. Co-founder and CEO Andrew Dudum said, “More than 2.5 million subscribers now rely on us,” adding the company believes it is “well on our way to becoming the global leader in consumer health.” Dudum stated that in 2025 the company expanded access to care “across an expanding range of conditions,” including “launching hormone therapies and diagnostics” and “introducing Labs,” while taking steps “to grow internationally.” He added that the “continued growth and diversification of our platform” supports proactive and personalized care.
Hims & Hers Health, Inc. (NYSE:HIMS) operates a consumer-first health and wellness platform connecting consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
